Christopher Kenney
Chief Tech/Sci/R&D Officer chez XENON PHARMACEUTICALS INC.
Fortune : - $ au 31/03/2024
Profil
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously worked as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2016 to 2019, as the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and as the Senior Vice President-Clinical Development at Biotie Therapies, Inc. from 2013 to 2016.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Christopher Kenney
| Sociétés | Poste | Début |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 23/08/2021 |
Anciens postes connus de Christopher Kenney
| Sociétés | Poste | Fin |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/12/2020 |
| ACORDA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
| Biotie Therapies, Inc. | Chief Tech/Sci/R&D Officer | 01/01/2016 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Biotie Therapies, Inc. |
